drugset / Trial / NCT04051047
Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma
Phase 0
Withdrawn
University of Michigan Rogel Cancer Center
University of Colorado, Denver · collab
NaSingle-groupOpen-labelBasic science
Summary
The primary aim of this study is to determine the presence of gemcitabine in childhood diffuse midline gliomas (DMG) (previously classified as diffuse intrinsic pontine glioma \[DIPG\]) after systemic treatment with the drug.
Timeline
- Start
- 2019-11-30
- Primary completion
- 2021-12
- Completion
- 2021-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 2100 mg/m2 | Intravenous |